Rilonacept ( DrugBank: Rilonacept )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
106	クリオピリン関連周期熱症候群	3
107	若年性特発性関節炎	2
266	家族性地中海熱	1

51. 全身性強皮症

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01538719 (ClinicalTrials.gov)	December 2011	21/2/2012	IL1-TRAP, Rilonacept, in Systemic Sclerosis	Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial	Scleroderma;Systemic Sclerosis;Diffuse Scleroderma;Diffuse Systemic Sclerosis	Drug: Rilonacept;Other: Placebo	Boston University	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	24	Phase 1/Phase 2	United States

106. クリオピリン関連周期熱症候群

臨床試験数 : 42 / 薬物数 : 24 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01045772 (ClinicalTrials.gov)	January 2009	7/1/2010	Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)	A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)	Muckle-Wells Syndrome;Schnitzler Syndrome	Drug: rilonacept	Charite University, Berlin, Germany	NULL	Completed	18 Years	N/A	Both	10	Phase 2	Germany
2	EUCTR2006-004290-97-DE (EUCTR)	19/12/2008	17/10/2006	A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1	A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1	The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis.	Trade Name: Rilonacept	Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy	NULL	Not Recruiting			Female: yes Male: yes			Germany
3	NCT00288704 (ClinicalTrials.gov)	December 2005	6/2/2006	Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)	IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs	Familial Cold Autoinflammatory Syndrome (FCAS);Familial Cold Urticaria;Muckle-Wells Syndrome (MWS);Genetic Diseases, Inborn	Drug: rilonacept 160 mg;Drug: Placebo	Regeneron Pharmaceuticals	NULL	Completed	7 Years	N/A	All	104	Phase 3	United States

107. 若年性特発性関節炎

臨床試験数 : 441 / 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00534495 (ClinicalTrials.gov)	November 2008	24/9/2007	Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults	Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)	Juvenile Idiopathic Arthritis	Biological: Rilonacept	Montefiore Medical Center	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Months	19 Years	All	71	Phase 2	United States
2	NCT01803321 (ClinicalTrials.gov)	November 2005	28/2/2013	Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	Systemic Juvenile Idiopathic Arthritis	Drug: rilonacept (IL-1 Trap);Other: Placebo	Regeneron Pharmaceuticals	NULL	Completed	4 Years	20 Years	Both	24	Phase 1	United States

266. 家族性地中海熱

臨床試験数 : 28 / 薬物数 : 24 - (DrugBank : 6) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 59

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00582907 (ClinicalTrials.gov)	August 2008	19/12/2007	Rilonacept for Treatment of Familial Mediterranean Fever (FMF)	Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)	Familial Mediterranean Fever	Drug: Rilonacept;Drug: Placebo	The Cleveland Clinic	NULL	Completed	4 Years	N/A	All	14	Phase 2	United States

先頭へ